Key Points
- Christopher Richard Anzalone sold 13,187 ARWR shares on Jan 2 at about $66.10 for ~$871,660, leaving him with 3,792,739 shares (≈$250.7M) and a 0.35% reduction in ownership.
- This sale is part of a recent string of insider disposals from Dec 15–Jan 2 totaling roughly $24.0 million across multiple transactions, including large blocks of 130,000 and 85,000 shares.
- Arrowhead has a market cap of $8.68 billion and a consensus analyst rating of "Moderate Buy" with a $61.89 price target; the stock's 1‑year range is $9.57–$72.36.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 13,187 shares of the firm's stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $66.10, for a total value of $871,660.70. Following the completion of the transaction, the chief executive officer directly owned 3,792,739 shares of the company's stock, valued at approximately $250,700,047.90. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Christopher Richard Anzalone also recently made the following trade(s):
- On Monday, December 29th, Christopher Richard Anzalone sold 51,726 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $69.13, for a total transaction of $3,575,818.38.
- On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.44, for a total transaction of $861,385.84.
- On Friday, December 19th, Christopher Richard Anzalone sold 13,445 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $67.66, for a total transaction of $909,688.70.
- On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $64.04, for a total transaction of $5,443,400.00.
- On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84.
- On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00.
Arrowhead Pharmaceuticals Price Performance
Shares of ARWR stock opened at $63.88 on Tuesday. The firm has a market cap of $8.68 billion, a price-to-earnings ratio of -798.40 and a beta of 1.21. The stock's fifty day simple moving average is $55.20 and its 200 day simple moving average is $35.35. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $72.36. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
Institutional investors have recently bought and sold shares of the company. iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $29,000. Salomon & Ludwin LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth $34,000. Federated Hermes Inc. bought a new position in Arrowhead Pharmaceuticals in the third quarter valued at $52,000. Smartleaf Asset Management LLC increased its stake in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,618 shares during the last quarter. Finally, Virtus Advisers LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth about $34,000. Institutional investors own 62.61% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently commented on the company. Bank of America increased their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a "buy" rating in a research report on Tuesday, December 9th. Royal Bank Of Canada increased their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an "outperform" rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. The Goldman Sachs Group increased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a "neutral" rating in a report on Thursday, November 20th. Finally, Piper Sandler raised their price target on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.89.
View Our Latest Research Report on Arrowhead Pharmaceuticals
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
